Capricor Therapeutics stock analysis
Capricor Therapeutics (0HTB) Share Price & Analysis
0HTB Stock Chart & Stats
- Day’s Range
- N/A
- 52-Week Range
- N/A
- Previous Close
- N/A
- Volume
- N/A
- Average Volume (3M)
- N/A
- Market Cap
- EUR 589.68M
- Enterprise Value
- EUR 445.13M
- Total Cash (Recent Filing)
- EUR 237.93M
- Total Debt (Recent Filing)
- EUR 91.05M
- Price to Earnings (P/E)
- ―
- Beta
- N/A
- Next Earnings
- Mar 11, 2027 (Est.)
- EPS Estimate
- -0.33
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy
The pivotal HOPE-3 trial produced a statistically significant efficacy result, supporting deramiocel’s potential differentiation in Duchenne muscular dystrophy. A durable treatment effect in upper-limb function could address an important unmet need and provide a credible foundation for regulatory approval and eventual commercial adoption.
Durable Safety Profile
A favorable safety record across more than 1,300 infusions and continued follow-up in open-label studies reduces a key adoption barrier for a cell therapy. Sustained tolerability can support physician confidence, patient retention, and broader use if the product receives regulatory approval.
Launch Readiness And Liquidity
Capricor has progressed beyond clinical development planning toward commercialization, with launch functions and manufacturing capacity being prepared while management reports at least 12 months of funding. This provides operational flexibility to support regulatory execution and an initial launch without an immediate financing requirement.
Bears Say
No Commercial Revenue
The absence of recognized revenue confirms that Capricor remains dependent on regulatory success before establishing a recurring product-sales base. Until deramiocel is approved and launched, the company lacks commercial operating scale, making future progress highly dependent on development execution and external funding.
Regulatory Timing Risk
The extended FDA review delays resolution of the central approval milestone and prolongs the period before Capricor can convert clinical progress into product revenue. Additional review time also increases execution uncertainty around launch timing, spending requirements, and the company’s ability to maintain momentum.
Distribution Dispute
The unresolved distribution dispute creates uncertainty around the commercial path for deramiocel and has required Capricor to prepare for independent commercialization. That could increase internal execution demands and complicate future distribution arrangements even if regulatory approval is obtained.
Capricor Therapeutics News
0HTB FAQ
What is Capricor Therapeutics’s market cap?
When is Capricor Therapeutics’s upcoming earnings report date?
How were Capricor Therapeutics’s earnings last quarter?
Is Capricor Therapeutics overvalued?
Does Capricor Therapeutics pay dividends?
What is Capricor Therapeutics’s EPS estimate?
What happened to Capricor Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Capricor Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Capricor Therapeutics Stock Smart Score
Company Description
Capricor Therapeutics
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Linda Marbán
- Employees
- 231
- Website
- www.capricor.com
- Address
- 10865 Road to the Cure, San Diego, CA, 92121, US
Capricor Therapeutics (0HTB) Earnings & Revenues
0HTB Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive, supported by a statistically significant HOPE-3 primary endpoint, favorable two-year extension and integrated-trial data, positive safety experience, cardiac-data recognition, FDA review progress, launch preparation, manufacturing readiness, and a cash runway of at least 12 months. Key negatives were the still-pending FDA decision, the ongoing NS Pharma dispute, no recognized revenue, higher operating expenses, larger net losses, a nonsignificant overall ejection-fraction result, and a 10% workforce reduction. The highlights significantly outweighed the lowlights.
View all GB:0HTB earnings summaries